EYE — Nova Eye Medical Income Statement
0.000.00%
Last trade - 00:00
- AU$58.98m
- AU$57.58m
- AU$17.13m
- 70
- 25
- 84
- 63
R2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 16.3 | 12.8 | 13.6 | 13.4 | 17.1 |
Cost of Revenue | |||||
Gross Profit | 13.3 | 9.8 | 11.4 | 11.1 | 14.5 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 24.4 | 19.9 | 18.6 | 23.3 | 35.1 |
Operating Profit | -8.05 | -7.12 | -4.93 | -9.92 | -17.9 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -7.96 | -7.25 | -5.25 | -8.25 | -17 |
Provision for Income Taxes | |||||
Net Income After Taxes | -6.66 | -10.3 | -4.36 | -7.5 | -15.3 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -5.77 | 35.7 | -4.36 | -7.5 | -15.3 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -5.77 | 35.7 | -4.36 | -7.5 | -15.3 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.045 | -0.07 | -0.03 | -0.05 | -0.071 |
Special Dividends per Share |